Variation in Supportive Care Practices in Hematopoietic Cell Transplantation  by Lee, Stephanie J. et al.
Variation in Supportive Care Practices
in Hematopoietic Cell Transplantation
Stephanie J. Lee,1 Claudia C. Astigarraga,1 Mary Eapen,2 Andrew S. Artz,3 Stella M. Davies,4
Richard Champlin,5 Madan Jagasia,6 Nancy A. Kernan,7 Fausto R. Loberiza, Jr.,8
Margaret Bevans,9 Robert J. Soiffer,10 Steven Joffe11
Hematopoietic cell transplantation is an elective procedure that results in prolonged immune suppression
and high treatment-related morbidity and mortality. Transplant centers and physicians use a variety of pro-
phylaxis and monitoring strategies to prevent or minimize complications. Little is known about the variability
in these practices. We conducted an international Internet-based survey of 526 physicians to describe the
spectrum of supportive care practices employed. Consistency in pretransplant cardiac (96%) and pulmonary
(95%) screening, informed consent documentation (93%), and use of antifungal prophylaxis (92%) was ob-
served. Greater heterogeneity was seen in use of myelogenous growth factors, empiric antibiotic therapy,
protective isolation procedures, posttransplant monitoring, and environmental and social restrictions. Al-
though some practice differences were associated with physician characteristics and transplant type, most
practice variation remained unexplained. These results suggest a need for well-designed observational and
interventional studies to provide data about which supportive care practices improve outcomes. For prac-
tices proved to be beneficial, publication of guidelines and incorporation of monitoring into quality improve-
ment initiatives may help standardize practices.
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Hematopoietic cell transplantation (HCT) is
a procedure in which high risks of morbidity and
potential mortality are accepted by patients, families,
and physicians in pursuit of curative or life-prolonging
treatment. HCT is a complex medical treatment
performed by multidisciplinary teams of physicians,
nurses, pharmacists, psychosocial personnel, and other
clinical staff within specialized treatment units. Pa-
tients are at high risk for organ toxicity, infections,
and other life-threatening treatment complicationsfor a prolonged period. As a result, a number of pre-
vention and monitoring strategies and supportive
care practices are common in HCT, although many
of these practices have never been studied rigorously.
The best-studied data about supportive care practices
derives from randomized trials using prophylactic
pharmacologic agents such as ursodeoxycholic acid,
hematopoietic growth factors, and antiinfective agents
[1–7]. Considerably less information is available about
the effectiveness of protective isolation procedures and
posttransplant monitoring, although practices have
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clude the small number of HCT patients per center,
lack of interest or funding to pursue studies in support-
ive care, methodologic and logistical issues in conduct-
ing supportive care intervention studies, and great
variability in other treatment practices that might ob-
scure definitive conclusions even if such studies could
be organized. Controlled trials may not be feasible for
some approaches. In the absence of data, individual phy-
sicians and programs typically develop practice policies
based upon local opinion, experience, and resources.
To better understand the breadth of variation in
supportive care practices, we conducted an Internet-
based international survey of transplant physicians.
Although the main purpose of the current report is
descriptive, we hypothesized that evaluation and sup-
portive care practices may differ according to whether
physicians performed primarily adult autologous,
adult allogeneic myeloablative, adult allogeneic re-
duced-intensity conditioning (RIC) or pediatric pro-
cedures, because of differences in perceived risks for
various complications.
METHODS
Physician Survey
Items were constructed to capture data about rou-
tine practices, including supportive care, usually used
or recommended by the respondent. The self-adminis-
tered survey contained 44-50 items and took 10-20
minutes to complete. The first section contained 8
questions about preparation before HCT, including
the requirement for informed consent even if not on
a clinical trial, pre-HCT physiologic testing, and at-
tention to advance care planning and psychosocial
issues. Clinical practices during HCT were assessed
by 10 questions covering infectious prophylaxis, use
of supportive care interventions, reverse isolation pro-
cedures, and management of fever without a clear
source. Five questions collected data about practices
after HCT, including routine testing and protective
isolation restrictions. All questions asked physicians
what they ‘‘routinely’’ did for the major population
of patient they treated. The final section of 11
questions collected physician and transplant center
characteristics. Data derived from questions about in-
dications for HCT and prophylaxis and management
of graft-versus-host disease (GVHD) have been
previously reported [10]. A copy of the survey may
be obtained from the corresponding author.
Data Collection
The Dana-Farber Cancer Institute’s institutional
review board approved the study and waived the re-
quirement for documentation of informed consent.
Data collection procedures have been previouslyreported [10]. Briefly, a description of the survey and
invitation to participate were emailed to a list main-
tained by the Center for International Blood and Mar-
row Transplant Research (CIBMTR). Each invitation
included a unique link to allow survey completion or
opting out. Three e-mail reminders were subsequently
sent at weekly intervals. Surveying occurred between
November 18, 2005, and December 15, 2005.
There were 2229 e-mails sent to potentially eligi-
ble subjects. Of these, 407 were not eligible to respond
because of confirmation of undeliverable e-mail, dupli-
cate addresses, or confirmation that the recipient was
ineligible (eg, not a transplantation physician, retired);
540 responses were received, of which 526 were evalu-
able. Surveys (n5 14) were excluded if respondents an-
swered fewer than half of the medical decision making
or supportive care questions. Only 84 recipients
actively declined to participate in the study; 1036 did
not respond in any way to the 3 e-mails and we are
unable to further classify this group into passive nonre-
spondents versus inactive e-mail addresses. Thus,
the evaluable response rate was 526 of 627 (84%)
confirmed invitations or 526 of 1823 (29%) of all
invitations.
Biostatistical Analysis
Descriptive statistics are reported for sociodemo-
graphics and practice characteristics according to
whether physicians self-identified primarily as adult
autologous (n 5 152), adult allogeneic myeloablative
(n 5 178), adult allogeneic reduced intensity condi-
tioning (n 5 54), or pediatric practitioners (n 5 142).
Individual respondents were considered inevaluable
for particular questions if either they did not answer
the question, indicated they did not see those types
of patients, or otherwise indicated the question did
not pertain to them.
Logistic and linear modeling approaches were
used to examine associations between physician char-
acteristics and various supportive care practices. The
physician characteristics we evaluated included: pre-
dominant type of procedure performed (adult autolo-
gous, adult allogeneic myeloablative, adult allogeneic
RIC, and pediatric), year training completed (dichoto-
mized at the median: before 1991, 1991, or later), sex,
affiliation (academic, community, or both), center size
(dichotomized at the median number of annual trans-
plants: 70), percentage of time devoted to patient care
(\60%, 60%, or more), and clinical research (\20%
vs. 20% or more), and country (United States, other)
as potential predictors. The multivariate analyses
were limited to the 500 physicians for whom we had
complete demographic and practice data.
For the social and environmental recommended
protective practices, respondents were asked ‘‘Please
tell us how long you recommend limitations on the
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ents, assume the patient does not have acute or chronic
GVHD [aGVHD, cGVHD]).’’ A summary variable
called the ‘‘total isolation score’’ was created by sum-
ming the responses to the 7 questions. Each item score
ranged from 1 (no restrictions) to 5 (.1 year) with
a possible range of 7-35, with lower score indicating
less restrictive policies. Forward stepwise selection
methods were used, and variables with P\ .05 were
retained in the final model.
RESULTS
Physician Characteristics
Physician and center descriptions are presented in
Table 1 according to the self-identified physician
group. Most characteristics were similar across the4 groups. Of the 142 pediatricians, 124 (87%) practiced
myeloablative procedures, 13 (9%) RIC procedures,
and 5 (4%) autologous procedures.
Preparation before Transplantation
There was strong agreement on evaluation and
counseling practices prior to HCT (Table 2). The ma-
jority endorsed measuring cardiac function (96%),
pulmonary function tests (95%), having all patients
give written informed consent even if not on a clinical
trial (93%), and having a psychosocial provider meet
with the patient before scheduling HCT (83%). Dis-
cussion of advance care planning issues was reported
commonly in all groups. Overall, 38% reported giving
postpubertal females leuprolide to suppress menses.
Of physicians primarily practicing allogeneic trans-
plantation, 130 of 355 (37%) have a psychosocial pro-
vider meet with donors, whereas 45 of 343 (13%)Table 1. Physician and Center Characteristics*
Adult
Autologous
Adult Allogeneic
-Myeloablative
Adult Allogeneic –Reduced-Intensity
Conditioning Pediatricians
N (%) 152 (29) 178 (34) 54 (10) 142 (27)
Age, median years, range† 48 (31-68) 47 (33-72) 47 (31-63) 46 (32-68)
Sex, n (%)
Men 115 (76) 150 (84) 38 (70) 87 (61)
Women 32 (21) 24 (13) 15 (28) 54 (38)
Missing 5 (3) 4 (2) 1 (2) 1 (1)
Year completed training, n (%)
Before 1980 19 (13) 20 (11) 7 (13) 12 (8)
1980-1989 45 (30) 55 (31) 18 (33) 40 (28)
1990-1999 65 (43) 75 (42) 17 (31) 59 (42)
2000 or later 17 (11) 25 (14) 11 (20) 27 (19)
Missing 6 (4) 3 (2) 1 (2) 4 (3)
Practice setting, n (%)
Academic center 90 (59) 136 (76) 48 (89) 108 (76)
Community setting 27 (18) 13 (7) 0 (0) 9 (6)
Both academic and community 31 (20) 27 (15) 5 (9) 23 (16)
Missing 4 (3) 2 (1) 1 (2) 2 (1)
Percentage of time, median†
Patient care 65 50 50 50
Administration/teaching 15 20 20 20
Basic research 0 0 0 0
Clinical research 10 20 20 20
Attending responsibilities, median†
Days in clinic 3 days 3 days 3 days 2 days
Months on an inpatient service 4 months 4 months 4 months 4 months
Total annual HCT procedures at center, median† 60 100 95 40
Procedures at center, median %†
Autologous 65 30 40 30
Myeloablative allogeneic 20 45 20 60
Reduced intensity conditioning 14 20 40 5
Country, n (%)
United States 88 (58) 83 (47) 32 (59) 98 (69)
Other 59 (39) 92 (52) 21 (39) 41 (29)
Missing 5 (3) 3 (2) 1 (2) 3 (2)
Region, n (%)
North America 99 (65) 93 (52) 33 (61) 105 (74)
South America 13 (9) 15 (8) 4 (7) 5 (4)
Europe 18 (12) 43 (24) 11 (20) 15 (11)
Asia 7 (5) 17 (10) 4 (7) 8 (6)
Africa 0 (0) 2 (1) 1 (2) 0 (0)
Australia/New Zealand 10 (6) 5 (3) 0 (0) 6 (4)
Missing 5 (3) 3 (2) 1 (2) 3 (2)
*Percentages may not equal 100% because of rounding.
†Based on available data, missing 2-7 responses per question.
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Total*
Adult
Autologous†
Adult Allogeneic–
Myeloablative‡
Adult Allogeneic–
Reduced- Intensity Condioning§ Pediatricians¶
Measure cardiac left ventricular function, n (%) 503 (96) 151 (100) 162 (93) 50 (93) 140 (99)
Measure pulmonary function tests, n (%) 493 (95) 145 (97) 165 (95) 48 (89) 135 (95)
Have all patients sign an informed consent
document for HCT, even if not on a clinical
trial, n (%)
480 (93) 136 (90) 164 (94) 51 (100) 129 (93)
Have a psychosocial provider (psychiatrist, psychologist,
social worker) meet with the patient before he or
she is scheduled for HCT, n (%)
431 (83) 125 (83) 132 (76) 41 (76) 133 (94)
Discuss advance care planning issues (eg, surrogate
decision maker, life support options), n (%)
373 (74) 109 (73) 128 (74) 47 (87) 89 (71)
Give postpubertal females leuprolide to suppress
menses, n (%)
191 (38) 42 (29) 61 (35) 21 (40) 67 (51)
Have a psychosocial provider (psychiatrist, psychologist,
social worker) meet with donors, n (%)6
130 (37) n/a 43 (25) 16 (30) 71 (55)
Collect back up autologous stem cells before unrelated
donor HCT, n (%)^
45 (13) n/a 25 (15) 7 (14) 13 (10)
*Missing 4-22 responses.
†Missing 1-9 responses.
‡Missing 3-12 responses.
§Missing 0-4 responses.
¶Missing 0-16 responses.
^Allogeneic practitioners only.collect backup autologous stem cells before unrelated
donor HCT.
Factors associated with discussion of advance care
planning issues, giving postpubertal females leupro-
lide, and having a psychosocial provider meet with do-
nors were explored. In multivariate analysis (n5 476),
discussion of advance care planning was associated
with participation in clinical research (odds ratio
[OR] 1.6, P 5 .02) and practicing in the United States
(OR 1.6, P 5 .03). Prescribing leuprolide to postpu-
bertal women was associated with being a pediatrician
(OR 1.9, P5 .005) and a female physician (OR 1.6, P5
.03). Of physicians practicing primarily allogeneic
transplantation, pediatricians (OR 3.9, P \ .0001)
and physicians spending .60% clinical time (OR
1.7, P 5 .04) were more likely to have donors meet
with psychosocial providers.
Infectious Disease Practices
Table 3 shows reported infectious disease prac-
tices. Most respondents (92%) reported routine use
of antifungal prophylaxis. Prescribing myelogenous
growth factors was more common among US physi-
cians (OR 3.4 P\ .0001), smaller centers (OR 1.9, P
5 .001), and adult autologous transplant physicians
(OR 2.9, P\ .0001). Routine antibiotic prophylaxis
was more common in the United States (OR 1.7, P
5 .01) and less common among pediatricians (OR
0.3, P\ .0001). Considerable heterogeneity in practice
was seen in empiric treatment of neutropenic fever,
viral monitoring and prophylaxis, and inpatient pro-
tective isolation procedures.Supportive Care and Monitoring during and
after Transplantation
Table 4 shows frequency of prophylactic urso-
deoxycholic acid use, routine posttransplant restaging
of patients with acute myelogenous leukemia (AML),
and use of routine pulmonary function testing after
transplantation. Depending on the group, ursodeoxy-
cholic acid prophylaxis use was prescribed by 22% to
40% of respondents. Routine use of ursodeoxycholic
acid was predicted by performing adult allogeneic
myeloablative procedures (OR 1.8, P5 .005), practic-
ing in the United States (OR 1.7, P5 .01), and\60%
clinical time (OR 1.7, P 5 .006). Pediatricians were
more likely than adult transplant physicians to obtain
routine pulmonary function tests after transplantation.
Protective Isolation
After transplantation, policies on environmental
and social restrictions were highly variable, as shown
in Table 5. The overall median ‘‘total isolation score’’
was 17 with a range of 7-33. In multivariate modeling,
pediatricians (median total isolation score 5 19) were
the most restrictive, followed by adult allogeneic mye-
loablative (median 5 17), adult allogeneic RIC (me-
dian 5 16), then adult autologous providers (median
5 15) (P \ .0001). Younger physicians were more
restrictive than older physicians (P 5 .002).
DISCUSSION
We report the results of a cross-sectional survey of
526 adult and pediatric HCT physicians participating
in the CIBMTR. We found a high degree of
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Practice
Adult
autologous*
Adult allogeneic
-myeloablative†
Adult allogeneic –
reduced intensity
conditioning‡ Pediatricians§
Routine myelogenous growth factors, n (%) Yes 118 (79) 80 (45) 28 (52) 84 (60)
Routine antibacterial prophylaxis, n (%) Yes 118 (79) 136 (76) 41 (76) 71 (50)
Empiric treatment of neutropenic
fever, n (%)
 Single agent broad spectrum cephalosporin,
beta-lactam or carbapenem
84 (56) 105 (59) 30 (56) 67 (47)
 Combination therapy with 1 of the above
and an aminoglycoside
46 (30) 59 (33) 16 (30) 48 (34)
 Alternative antibiotic regimen 21 (14) 14 (8) 8 (15) 27 (19)
Routine antifungal prophylaxis, n (%) Yes 137 (91) 160 (90) 49 (91) 136 (96)
Routine acyclovir or similar antiviral
prophylaxis, n (%)
 Yes, regardless of herpes simplex virus status 79 (52) 110 (62) 36 (67) 56 (39)
 Yes, if herpes simplex virus positive 65 (43) 60 (34) 11 (20) 84 (59)
 No 7 (5) 8 (4) 7 (13) 2 (1)
Management of cytomegalovirus, n (%)¶  Monitoring by PCR testing, preemptive therapy 77 (53) 99 (56) 33 (61) 100 (70)
 Monitoring by antigenemia testing,
preemptive therapy
51 (35) 98 (55) 24 (44) 44 (31)
 Antiviral prophylaxis with ganciclovir
or foscarnet
17 (12) 22 (12) 4 (7) 21 (15)
 No routine management strategy 6 (4) 0 (0) 0 (0) 3 (2)
Isolation during hospitalization, n (%)¶  Hepa-filtration 110 (73) 153 (86) 40 (74) 122 (86)
 Masks 50 (33) 93 (52) 26 (48) 53 (37)
 Laminar-airflow rooms 39 (26) 62 (35) 15 (28) 46 (32)
 Gloves 39 (26) 66 (37) 21 (39) 32 (23)
 Gowns 32 (21) 60 (34) 13 (24) 38 (27)
 Gut decontamination 22 (15) 50 (28) 11 (20) 27 (19)
 Shoe covers 24 (16) 32 (18) 7 (13) 22 (15)
*Missing 1-3 responses.
†Missing 0-1 responses.
‡No missing responses.
§Missing 0-2 responses.
¶Categories not mutually exclusive. Percentages may add to >100%.agreement about certain practices such as pre-HCT
organ function measurement and posttransplant rou-
tine antifungal prophylaxis. Use of other practices,
however, was much more heterogeneous.
One of the purposes of the pre-HCT evaluation is
to ensure that patients have adequate organ function to
meet clinical and protocol requirements for HCT. Al-
though it is customary to require a certain minimum
cardiac left ventricular function and pulmonary func-
tion testing results to proceeding with transplantation,
it is not clear how physicians otherwise use these
results to adjust treatment plans or counsel patients
differently about risks [11,12]. More than 90% of phy-
sicians have all patients sign informed consent docu-ments for HCT, reflecting a firm belief in the need
for written documentation of a patient’s agreement
to the procedure. Between 71% and 87% of respon-
dents reported discussions of advance care planning
issues with their patients, a much higher percentage
than suggested by single institution studies [13,14].
Another purpose of the pre-HCT evaluation is to
prepare patients mentally to undergo transplantation.
Eighty-three percent of physicians had their patients
met with a psychologist or social worker prior to
HCT. Although psychosocial evaluation is unlikely
to alter the treatment plan [15,16], the support of a psy-
chologist and/or social worker prior to and during
HCT may alter the level of distress experienced byTable 4. Supportive Care and Monitoring Practices during and after Transplantation
Practice
Adult
autologous*
Adult Allogeneic -
Myeloablative†
Adult Allogeneic–
Reduced- Intensity
Conditioning‡ Pediatricians§
Prophylactic use of ursodeoxycholic acid, n (%) Yes 33 (22) 71 (40) 21 (39) 58 (41)
Routinely restage patients with acute
myelogenous leukemia at specific
time point(s), n (%)
Yes 100 (66) 137 (77) 41 (77) 76 (54)
No, only according to clinical status 40 (26) 40 (23) 11 (21) 64 (45)
Not applicable 11 (7) 0 (0) 1 (2) 2 (1)
Routinely perform pulmonary function tests at
specific time point(s) after transplantation in
asymptomatic patients, n (%)
Yes 39 (26) 82 (46) 18 (34) 113 (80)
No, only if symptoms 90 (60) 74 (42) 27 (51) 18 (13)
Only if other chronic GVHD signs 21 (14) 21 (12) 8 (15) 11 (8)
GVHD indicates graft-versus-host disease.
*Missing 1-2 responses.
†Missing 1 responses.
‡Missing 0-1 responses.
§No missing responses.
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Length of Recommended Limitations, %*
Practice No restrictions 1-99 days 100 days to 6 months 6-12 months >1 year
Outdoor public places (parks, walk around neighborhood) 45 34 16 5 1
Visitors in the home 37 43 15 5 1
Masks and/or gloves in public 34 41 18 7 1
Take out foods 21 39 23 14 4
Indoor public places (restaurants, shopping, movies) 12 42 29 15 2
Work in an office or school 5 18 35 37 6
Raw seafood 5 21 19 25 30
GVHD indicates graft-versus-host diseases.
Physicians treating allogeneic recipients were instructed to assume no acute or chronic GVHD.
*Eight to 11 responses not evaluable, may total >100% because of rounding.patients and their families. Some studies have observed
an association between pre-HCT psychosocial distress
and higher mortality after HCT [17,18]. The Institute
of Medicine recently concluded that inadequate atten-
tion to psychosocial problems associated with cancer
care can lead to compromise in the effectiveness of
health care and the overall health of the cancer patients
[19]. One barrier to more frequent referral may be the
availability of support staff; a previous study suggested
that between 20% and 50% of centers do not have ded-
icated psychosocial support staff [20].
Several infectious disease practices also varied sub-
stantially. Routine myelogenous growth factor use by
adult autologous transplant physicians was higher
than adult allogeneic or pediatric physicians, but still
not consistent with published guidelines, which rec-
ommend its use in autologous but not allogeneic trans-
plantation using adult or child donors [1]. Routine use
of antibacterial prophylaxis was common among adult
transplant physicians but less common in pediatrics. In
contrast, routine antifungal prophylaxis was common
in all groups, as supported by data from a randomized
trial [3]. Other infection prevention procedures during
hospitalization varied substantially. Hepa-filtration
was widespread, whereas shoe covers and gut decon-
tamination were the least common.
Supportive care and monitoring during and after
transplantation also varied. Fewer than half of alloge-
neic practitioners routinely prescribe urodeoxycholic
acid, although several studies have shown improved
outcomes in both adults and children [4-7]. Routine
restaging of patients with AML and pulmonary func-
tion testing after HCT was common, but not univer-
sal. In particular, 42% to 51% of adult allogeneic
transplant physicians would order pulmonary function
tests only if the patient had symptoms. In patients di-
agnosed with cGVHD, routine pulmonary function
testing is recommended to detect unsuspected airflow
obstruction, which may not become symptomatic until
extensive irreversible damage has occurred [21].
Protective social and environmental isolation re-
strictions following transplantation appear common,
and are predicted by both physician characteristics
and transplant type. Scant data provide guidance forrecommendations [22-26], although it has been argued
that common sense should prevail in these situations
[27]. During hospitalization, protective isolation may
exacerbate emotional isolation [28-31]. Anecdotally,
many patients strictly abide by dietary, hygienic, and so-
cial contact restrictions, which may contribute to social
isolation. Unless avoidance of friends, public places, and
work/school for prolonged periods improves outcomes,
liberalization of policies might facilitate resumption of
important roles and reintegration into society.
A number of caveats to our conclusions should be
noted. First, the common practices may reflect exter-
nal factors rather than physician prerogative. For ex-
ample, the homogeneity in pretransplant testing may
relate to insurance or to institutional or protocol re-
quirements, rather than to physicians’ beliefs about
their necessity for individual patient care. If so, then
their ubiquity highlights the opportunities to enforce
proven supportive care practices through accrediting
approaches or quality measures. We also caution that
results should be interpreted with the awareness that
these are self-reported physician practices from a sub-
set of practitioners. Physicians may endorse what they
believe the standard of care should be (eg, discussing
advance care directives) rather than their actual prac-
tices. Respondents may represent a select group of mo-
tivated and interested physicians more inclined than
nonrespondents to be aware of and adhere to best prac-
tices. Finally, the survey instrument may lack precision
in capturing the range of practices or the ways in which
physicians modify their practices and recommenda-
tions based on individual patients’ risks.
In summary, our study suggests that there is
substantial variation in supportive care practices in
HCT. These data have several practical implications.
In some cases, published literature is available to bring
practices into better compliance with proved
approaches or consensus recommendations. Some
simple practices such as routine use of ursodeoxycholic
acid have been shown to improve outcome, but are still
used by only a minority of practitioners. Serial pulmo-
nary function tests are recommended to monitor
patients with cGVHD, but almost half of adult alloge-
neic transplant physicians would obtain them only if
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indicate that successful randomized studies alone or
published guidelines are not sufficient to change prac-
tice. Practice implementation studies, so-called ‘‘trans-
lational or T2’’ research, may be needed to identify
more effective strategies for incorporating clinical
guidelines into practice [32]. Second, in many cases
where resources are not available to conduct random-
ized trials, the intrinsic heterogeneity of supportive
care practices offers an opportunity to compare out-
comes in observational studies to determine best prac-
tices [20,33,34]. For example, our study suggests that if
detailed infection and outcome data were available,
one could compare practitioners who routinely in-
clude an aminoglycoside in their empiric neutropenic
fever regimens with those who do not. Third, knowl-
edge of practice variation can identify areas where ran-
domized trials may be possible. For instance, our
results indicate that approaches to menses suppression
vary, and could be studied prospectively. Finally, doc-
umentation of practice variation and dissemination of
these results allows physicians to compare their prac-
tices with what others are doing in a way that may pro-
voke introspection. We believe that assessing practice
variation represents a promising tool to initiate the
process of improving transplant outcomes by identify-
ing practice variation patterns where further study
and/or education is warranted.
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